Pfizer is no longer just about COVID; the company reports solid results 💰

Pfizer has posted solid results for Q2 2026, which support the view that the company is becoming less reliant on its Covid-related business and is generating increasing revenue from its other, ‘core’ products.

Quarterly results

• Revenue: US$15.03 billion vs. consensus of US$14.41 billion (+3% y/y)

• Adj. EPS: US$0.77 vs. US$0.68 expected

• GAAP net loss: US$248 million (EPS: US$-0.04), compared with a profit of US$2.91 billion a year earlier – the difference is mainly due to one-off restructuring costs and write-downs of intangible assets

• Eliquis (an anticoagulant, co-marketed with Bristol Myers Squibb): US$2.43 billion, +19% y/y, well above expectations (US$2.08–2.09 billion est.)

• Prevnar (vaccines): US$1.34 billion, slightly below the estimate of US$1.38 billion

It’s no longer just about COVID

Key takeaway from the report: revenue from non-COVID products rose by a further US$1.5 billion, enabling the company to raise the lower end of its full-year forecast. At the same time, the company lowered its revenue forecast for the COVID segment (vaccine + Paxlovid) to US$4 billion from the previous US$5 billion.

This shows a clear shift in the revenue structure – Pfizer is offsetting the decline in Covid-related sales by:

• Eliquis – rising sales thanks to better net prices in the US (lower discounts) and strong global demand

• Padcev – a targeted cancer drug – also helped to alleviate the strain on the Covid ward

• Acquired products – revenue from this segment rose by 25% on an operating basis year-on-year

Revision of forecasts

• Annual revenue: now US$60.5–62.5 billion (previously US$59.5–62.5 billion) – lower limit raised

• EPS (adjusted): unchanged, US$2.80–3.00 (takes into account the impact of US$650 million relating to the licence agreement with the Chinese company Innovent Biologics, worth up to US$10.5 billion)

• This range implies that sales will remain virtually flat or fall slightly compared with the US$62.6 billion figure for 2025

Cost-cutting – a new phase

Pfizer has announced an extension of its cost-cutting programme:

• New target: a total of US$6.7 billion in net savings (an increase on previous levels)

• A further US$2.5 billion in savings will be achieved between 2027 and 2029

• Focus on: improvements to the product portfolio, changes to the operational network structure, and further operational efficiency

• The first phase of the programme (US$1.5 billion) is on track to be completed by the end of 2027

Outlook – growth area: obesity

CEO Albert Bourla emphasised that “launched and acquired products performed well”, and that the obesity programme was “advancing with meaningful momentum”. This refers to the $10 billion acquisition of Metzer – Pfizer hopes this will enable it to establish a strong position in the rapidly growing market for obesity drugs (the GLP-1 segment). Investors are awaiting data from trials combining a GLP-1 injection with an amylin compound – this could be a key catalyst for the share price in the coming quarters.

The market reacted fairly calmly to the results – shares traded flat in pre-market trading, suggesting that the strong results had already been partly priced in, and that investors are waiting for more long-term evidence of the business’s transformation beyond the COVID-19 pandemic.

Since the Covid wave, PFE shares have been in a deep downtrend, constrained by exponential moving averages. Source: xStation